TetraLogic Pharmaceuticals (TLOG)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:TetraLogic Pharmaceuticals (TLOG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013224
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
TetraLogic Pharmaceuticals (TetraLogic) is a biopharmaceutical company that research and develops novel small molecule therapeutics in the areas of oncology and infectious diseases. The company’s clinical stage products include birinapant and SHAPE. Its birinapant is a small molecule therapeutic that causes cell death in damaged cells and is used in the treatment of hematological malignancies and solid tumors. TetraLogic carries out clinical trial to investigate the safety and effectiveness of different dosing regimens of SHAPE in patients suffering from earlier stage cutaneous T-cell lymphoma. The company conducts research and development to develop products for blood cancers, ovarian cancers, myelodysplastic syndromes, cutaneous T-cell lymphoma, hepatitis B and infectious diseases. TetraLogic is headquartered in Malvern, Pennsylvania, the US.

TetraLogic Pharmaceuticals (TLOG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Tetralogic Pharma Raises US$5 Million In Venture Financing 10
TetraLogic Pharma Secures US$6 Million In Series C-1 Financing 11
TetraLogic Pharma Secures US$23 Million In Second Tranche Of Series C Financing 12
Licensing Agreements 14
TetraLogic Pharma Enters Into Licensing Agreement With Walter And Eliza Hall Institute Of Medical Research 14
Equity Offering 15
TetraLogic Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$57.5 Million 15
Debt Offering 17
TetraLogic Pharma Raises USD47 Million in Private Placement of 8% Notes Due 2019 17
Asset Transactions 19
Medivir Acquires Two Clinical Stage Oncology Programs from Tetralogic Pharma 19
Acquisition 21
TetraLogic Pharma Acquires Shape Pharma 21
TetraLogic Pharmaceuticals – Key Competitors 22
TetraLogic Pharmaceuticals – Key Employees 23
TetraLogic Pharmaceuticals – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Jan 22, 2016: TetraLogic Pharmaceuticals Announces Workforce Reduction 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Key Facts, 2015 2
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TetraLogic Pharmaceuticals, Deals By Therapy Area, 2011 to YTD 2017 8
TetraLogic Pharmaceuticals, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Tetralogic Pharma Raises US$5 Million In Venture Financing 10
TetraLogic Pharma Secures US$6 Million In Series C-1 Financing 11
TetraLogic Pharma Secures US$23 Million In Second Tranche Of Series C Financing 12
TetraLogic Pharma Enters Into Licensing Agreement With Walter And Eliza Hall Institute Of Medical Research 14
TetraLogic Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$57.5 Million 15
TetraLogic Pharma Raises USD47 Million in Private Placement of 8% Notes Due 2019 17
Medivir Acquires Two Clinical Stage Oncology Programs from Tetralogic Pharma 19
TetraLogic Pharma Acquires Shape Pharma 21
TetraLogic Pharmaceuticals, Key Competitors 22
TetraLogic Pharmaceuticals, Key Employees 23
TetraLogic Pharmaceuticals, Subsidiaries 24

★海外企業調査レポート[TetraLogic Pharmaceuticals (TLOG)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pan-Provincial Vaccine Enterprise Inc-製薬・医療分野:企業M&A・提携分析
    Summary Pan-Provincial Vaccine Enterprise Inc (PREVENT) is a national vaccine commercialization consortium that specializes in research and development of vaccines for infectious diseases. The institute develops vaccines for infectious disease, group A streptococcus vaccine, chlamydia vaccine, influ …
  • ArQule Inc (ARQL):製薬・医療:M&Aディール及び事業提携情報
    Summary ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including …
  • Damodar Valley Corp:電力:M&Aディール及び事業提携情報
    Summary Damodar Valley Corp (DVC) is a government owned multi-purpose river valley project. It generates, transmits, and supplies electricity; mines for and produces coal; manages water and conserves soil; and provides consultancy services. The company produces energy using thermal and hydro sources …
  • CIC Private Banking:企業の戦略・SWOT・財務情報
    CIC Private Banking - Strategy, SWOT and Corporate Finance Report Summary CIC Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sunshine Oilsands Ltd (2012):企業の財務・戦略的SWOT分析
    Summary Sunshine Oilsands Ltd (Sunshine Oilsands) is an oil and gas company that develops holdings of oil sands and PN&G leases. The company owns and controls oil sands leases. Its properties include Thickwood, West Ells, Muskwa, Harper, Legend Lake and Portage, among others. Sunshine Oilsands also …
  • Holloway Lodging Corporation:戦略・SWOT・企業財務分析
    Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report Summary Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Moldex-Metric Inc:企業の戦略的SWOT分析
    Moldex-Metric Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ARM Holdings plc:企業のM&A・事業提携・投資動向
    ARM Holdings plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ARM Holdings plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Singapore Telecommunications Ltd:企業の戦略・SWOT・財務情報
    Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report Summary Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • SANUWAVE Health Inc (SNWV):企業の製品パイプライン分析2018
    Summary Sanuwave Health Inc (Sanuwave), formerly Rub Music Enterprises Inc, is a medical device company that develops and commercializes noninvasive biological response activating devices. The company offers products such as dermapace, which is used in the treatment of chronic and acute conditions o …
  • FMC Corp (FMC):企業の財務・戦略的SWOT分析
    FMC Corp (FMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • All in West! Capital Corp:企業の戦略・SWOT・財務分析
    All in West! Capital Corp - Strategy, SWOT and Corporate Finance Report Summary All in West! Capital Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Cornell University-医療機器分野:企業M&A・提携分析
    Summary Cornell University (CU) is an educational institute that offers graduate and undergraduate education and research services. The institute offers education in biological and environmental engineering, communication, crop and soil sciences, development sociology, biological statistics and comp …
  • Orchid Pharma Ltd (ORCHIDPHAR):企業の財務・戦略的SWOT分析
    Summary Orchid Pharma Ltd (Orchid), formerly Orchid Chemicals & Pharmaceuticals Ltd is a pharmaceutical company that develops and manufactures pharmaceutical solutions such as formulations and API products. The company offers formulations such as cardiovascular products, neuropsychiatry products, an …
  • Synchronoss Technologies, Inc. (SNCR):企業の財務・戦略的SWOT分析
    Synchronoss Technologies, Inc. (SNCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Diasome Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Diasome Pharmaceuticals Inc (Diasome) is a pharmaceutical company that focusses on clinical and commercial development of therapies for diabetes and obesity. The company offers products in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism. Its …
  • Southern Company Gas:企業の戦略的SWOT分析
    Southern Company Gas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Nippon Paint (China) Co Ltd:企業の戦略・SWOT・財務情報
    Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Benvenue Medical, Inc.:医療機器:M&Aディール及び事業提携情報
    Summary Benvenue Medical, Inc (Benvenue Medical) is a manufacturer, designer and distributor of minimally invasive systems and other medical devices. The product portfolio of the company includes Luna, a 3D interbody fusion system designed for the treatment to restore disc height. Blazer, is a verte …
  • Thor Mining Plc (THR):企業の財務・戦略的SWOT分析
    Summary Thor Mining Plc (Thor Mining) is a mining and mineral exploration and development company. The company carries out acquisition, exploration and develops gold, tungsten and molybdenum properties. Its projects include Molyhil Tungsten and Molybdenum, Spring Hill Gold, Dundas Gold project, and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆